References

mrj

Современная ревматология

Modern Rheumatology Journal

1996-70122310-158X

IMA-PRESS, LLC

10.14412/1996-7012-2021-2-112-119

mrj-1131

Research Article

ОБЗОРЫ

REVIEWS

Базисная терапия остеоартрита: современный взгляд на применение препаратов глюкозамина и хондроитина

Osteoarthritis background therapy: current view on the glucosamine and chondroitin therapy

https://orcid.org/0000-0001-7017-0898

Алексеева

Л. И.

Alekseeva

L. I.

Людмила Ивановна Алексеева

Кафедра ревматологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России

115522, Москва, Каширское шоссе, 34А,

125993, Москва, ул. Баррикадная, 2/1, стр. 1

Ludmila Ivanovna Alekseeva

Department of rheumatology Medical Academy of Continuing Professional Education

34A, Kashirskoe Shosse, Moscow 115522,

2/1, Barrikadnaya St., Build. 1, Moscow 125993

dr.alekseeva@gmail.com

https://orcid.org/0000-0002-6068-3080

Лила

А. М.

Lila

A. M.

115522, Москва, Каширское шоссе, 34А,

125993, Москва, ул. Баррикадная, 2/1, стр. 1

Department of rheumatology Medical Academy of Continuing Professional Education

34A, Kashirskoe Shosse, Moscow 115522,

2/1, Barrikadnaya St., Build. 1, Moscow 125993

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology, Moscow; Medical Academy of Continuing Professional EducationRussian Federation

2021

23042021

152112119

2021

Алексеева Л.И., Лила А.М.

Alekseeva L.I., Lila A.M.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://mrj.ima-press.net/mrj/article/view/1131

В статье освещены современные представления об использовании симптоматических средств замедленного действия (SYSADOA) при остеоартрите (ОА). Описаны механизмы их влияния, данные клинических исследований эффективности глюкозамина (ГЛ) и хондроитина сульфата (ХС) и их комбинации при ОА, подтверждающие наличие у этих препаратов симптоматического и структурно-модифицирующего действия. Рассмотрены последние рекомендации по лечению ОА лекарственными средствами этой группы, а также обоснования применения комбинированных препаратов хондроитина и ГЛ в качестве базисных средств на самых ранних стадиях развития ОА. Указано, что такая терапия должна быть длительной с учетом ее высокой безопасности, а также возможного снижения риска развития сердечно-сосудистых катастроф. Отмечено, что терапевтическими дозами ГЛ и ХС являются ≥1500 и ≥800 мг/сут соответственно, обращено внимание на преимущество капсулированных форм SYSADOA ввиду их фармакокинетических особенностей.

The article highlights the current status of symptomatic slow-acting drugs (SYSADOA) in osteoarthritis (OA). Mechanism of action, clinical studies data on the effectiveness of glucosamine (GA) and chondroitin sulfate (CS) and their combinations in OA, their positive symptomatic and structural-modifying effects, are described. The article provides the latest recommendations for the OA treatment with these two drugs and presents an argument for the combination therapy with both drugs as a background therapy in the earliest stages of OA. It is indicated that such therapy should be long-term due to its high safety and possible reduction of cardiovascular accidents risk as well. It is noted that therapeutic doses of CS and GA are ≥1500 and ≥800 mg per day, respectively, and encapsulated forms of SYSADOAs have advantages due to their pharmacokinetic features.

остеоартритрекомендациисимптоматические препараты замедленного действияхондроитинглюкозаминкомбинированные препараты

osteoarthritisrecommendationssymptomatic slow-acting drugschondroitinglucosaminecombined drugs

Статья спонсируется компанией «Байер»

This article has been supported by Вayer

References1

Kovari E, Kaposi A, Bekes G, et al. Comorbidity clusters in generalized osteoarthritis among female patients: A crosssectional study. Semin Arthritis Rheum. 2020 Apr;50(2):183-91. doi: 10.1016/j.semarthrit.2019.09.001. Epub 2019 Sep 9.

Балабанова РМ, Дубинина ТВ, Демина АБ, Кричевская ОА. Заболеваемость болезнями костно-мышечной системы в Российской Федерации за 2015–2016 гг. Научно-практическая ревматология. 2018;56(1):15-21.

Balabanova RM, Dubinina TV, Demina AB, Krichevskaya OA. The incidence of diseases of the musculoskeletal system in the Russian Federation for 2015–2016. Nauchno-prakticheskaya revmatologiya. 2018;56(1):15-21. (In Russ.).

GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1789-858. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8.

Felson DT, Lawrence RC, Dieppe PA, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000 Oct 17;133(8):635-46. doi: 10.7326/0003-4819-133-8-200010170-00016.

Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011 Jun 18; 377(9783):2115-26. doi: 10.1016/S0140-6736(11)60243-2.

Wallace IJ, Worthington S, Felson DT, et al. Knee osteoarthritis has doubled in prevalence since the mid-20th century. Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):9332-36. doi: 10.1073/pnas.1703856114. Epub 2017 Aug 14.

Zheng H, Chen C. Body mass index and risk of knee osteoarthritis: systematic review and meta-analysis of prospective studies. BMJ Open. 2015 Dec 11;5(12):e007568. doi: 10.1136/bmjopen-2014-007568.

Fu Y, Griffin TM. Obesity, Osteoarthritis And Aging: The Biomechanical Links. Mechanobiology Of Obesity And Related Diseases. Springer International Publishing; 2015. P. 181–201.

Wang H, Cheng Y, Shao D, et al. Metabolic Syndrome Increases the Risk for Knee Osteoarthritis: A Meta-Analysis. Evid Based Complement Alternat Med. 2016;2016: 7242478. doi: 10.1155/2016/7242478. Epub 2016 Oct 11.

Yoshimura N, Muraki S, Oka H, et al. Accumulation Of Metabolic Risk Factors Such As Overweight, Hypertension, Dyslipidaemia, And Impaired Glucose Tolerance Raises The Risk Of Occurrence And Progression Of Knee Osteoarthritis: A 3-Year Follow-Up Of The Road Study. Osteoarthritis Cartilage. 2012 Nov;20(11): 1217-26. doi: 10.1016/j.joca.2012.06.006. Epub 2012 Jul 14.

Bruyere O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014 Dec;44(3):253-63. doi: 10.1016/j.semarthrit.2014.05.014. Epub 2014 May 14.

Bruyere O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis – From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016 Feb;45(4 Suppl):S3-11. doi: 10.1016/j.semarthrit.2015.11.010. Epub 2015 Dec 2.

Arden NK, Perry TA, Bannuru RR, et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nat Rev Rheumatol. 2021 Jan;17(1):59-66. doi: 10.1038/s41584-020-00523-9. Epub 2020 Oct 28.

Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage. 1998 May;6 Suppl A:14-21. doi: 10.1016/s1063-4584(98)80006-x.

Алексеева ЛИ, Беневоленская ЛИ, Насонов ЕЛ и др. Структум (хондроитин сульфат) – новое средство для лечения остеоартроза (ОА). Терапевтический Архив. 1999;(5):51-3.

Alekseeva LI, Benevolenskaya LI, Nasonov EL, et al. Structum (chondroitin sulfate) – a new treatment for osteoarthritis (OA). Terapevticheskii Arkhiv. 1999;(5):51-3. (In Russ.).

Singh JA, Noorbaloochi S, MacDonald R, Maxwell LJ. Chondroitin for osteoarthritis. Cochrane Database Syst Rev. 2015 Jan 28; 1:CD005614. doi: 10.1002/14651858.CD005614.pub2.

Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum. 2005 Mar;52(3):779-86. doi: 10.1002/art.20867.

Kahan A, Uebelhart D, De Vathaire F, et al. Long-term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a twoyear, randomized, double-blind, placebocontrolled trial. Arthritis Rheum. 2009 Feb; 60(2):524-33. doi: 10.1002/art.24255.

Hochberg MC. Structure-modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta-analysis of randomized placebo-controlled trials of 2-year duration. Osteoarthritis Cartilage. 2010 Jun;18 Suppl 1:S28-31. doi: 10.1016/j.joca.2010.02.016. Epub 2010 Apr 27.

Railhac JJ, Zaim M, Saurel AS, et al. Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: a randomized, doubleblind, placebo-controlled pilot study using MRI. Clin Rheumatol. 2012 Sep;31(9): 1347-57. doi: 10.1007/s10067-012-2022-4. Epub 2012 Jun 23.

Verbruggen G, Goemaere S, Veys EM. Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clin Rheumatol. 2002 Jun;21(3):231-43. doi: 10.1007/s10067-002-8290-7.

Gabay C, Medinger-Sadowski C, Gascon D, et al. Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis: a randomized, double-blind, placebo-controlled clinical trial at a single center. Arthritis Rheum. 2011 Nov;63(11): 3383-91. doi: 10.1002/art.30574.

Du Souich P. Absorption, distribution and mechanism of action of SYSADOAS. Pharmacol Ther. 2014 Jun;142(3):362-74. doi: 10.1016/j.pharmthera.2014.01.002. Epub 2014 Jan 21.

Towheed TE, Maxwell L, Anastassiades TP, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002946. doi: 10.1002/14651858.CD002946.pub2.

Eriksen P, Bartels EM, Altman RD, et al. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: a metaanalysis of placebo-controlled trials. Arthritis Care Res (Hoboken). 2014 Dec;66(12): 1844-55. doi: 10.1002/acr.22376.

Gregori D, Giacovelli G, Minto C, et al. Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis. JAMA. 2018 Dec 25;320(24):2564-79. doi: 10.1001/jama.2018.19319.

Provenza JR, Shinjo SK, Silva JM, et al. Combined glucosamine and chondroitin sulfate, once or three times daily, provides clinically relevant analgesia in knee osteoarthritis. Clin Rheumatol. 2015 Aug;34(8):1455-62. doi: 10.1007/s10067-014-2757-1. Epub 2014 Aug 3.

Beaudart C, Lengele L, Leclercq V, et al. Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon. Drugs. 2020 Dec;80(18):1947-59. doi: 10.1007/s40265-020-01423-8.

Damlar I, Esen E, Tatli U. Effects of glucosamine-chondroitin combination on synovial fluid IL-1β, IL-6, TNF-α and PGE2 levels in internal derangements of temporomandibular joint. Med Oral Patol Oral Cir Bucal. 2015 May 1;20(3):e278-83. doi: 10.4317/medoral.20242.

Leffler CT, Philippi AF, Leffler SG, et al. Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, doubleblind, placebo-controlled pilot study. Mil Med. 1999 Feb;164(2):85-91.

66th Ann Meeting of AAOS. 1999. P.180

Das AK Jr, Hammad TA. Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage. 2000 Sep; 8(5):343-50. doi: 10.1053/joca.1999.0308.

Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006 Feb 23; 354(8):795-808. doi: 10.1056/NEJMoa052771.

Sawitzke AD, Shi H, Finco MF, et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum. 2008 Oct;58(10):3183-91. doi: 10.1002/art.23973.

Hochberg MC, Martel-Pelletier J, Monfort J. SAT0427 Multicentric Osteoarthritis Intervention Study with Sysadoa (MOVES): Effects of Combined Glucosamine Hydrochloride and Chondroitin Sulfate VS Celecoxib for Painful Knee Osteoarthritis. Ann Rheum Dis. 2014 Jun; 73(Suppl 2):749. doi: 10.1136/annrheumdis2014-eular.4950

Martel-Pelletier J, Roubille C, Abram F, et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis. 2015 Mar;74(3):547- 56. doi: 10.1136/annrheumdis-2013-203906. Epub 2013 Dec 13.

Fransen M, Agaliotis M, Nairn L, et al. LEGS study collaborative group. Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann Rheum Dis. 2015 May;74(5):851-8. doi: 10.1136/annrheumdis-2013-203954. Epub 2014 Jan 6.

Лила АМ. Терафлекс в комплексной терапии остеоартроза коленных суставов и остеохондроза позвоночника (результаты клинического исследования). Русский медицинский журнал. 2005;(24):1618-22.

Lila AM. Teraflex in the complex therapy of knee osteoarthritis and spinal osteochondrosis (results of a clinical study). Russkii meditsinskii zhurnal. 2005;(24):1618-22. (In Russ.).

Беневоленская ЛИ, Алексеева ЛИ, Зайцева ЕМ. Эффективность препарата терафлекс у больных остеоартрозом коленных и тазобедренных суставов (открытое рандомизированное исследование). Русский медицинский журнал. 2005; (8):525-7.

Benevolenskaya LI, Alekseeva LI, Zaitseva EM. Efficacy of teraflex in patients with osteoarthritis of the knee and hip joints (open randomized study). Russkii meditsinskii zhurnal. 2005;(8):525-7. (In Russ.).

Алексеева ЛИ, Кашеварова НГ, Шарапова ЕП и др. Сравнение постоянного и интермиттирующего лечения больных остеоартрозом коленных суставов комбинированным препаратом «Терафлекс». Научно-практическая ревматология. 2008; (3);68-72.

Alekseeva LI, Kashevarova NG, Sharapova EP, et al. Comparison of continuous and intermittent treatment of patients with osteoarthritis of the knee joints with the combined drug Teraflex. Nauchno-prakticheskaya revmatologiya. 2008;(3);68-72. (In Russ.).

Telyshev K, Alekseeva L, Lila A, et al. AB0885 Effectiveness and safety of glucosamine and chondroitin combination in patients with knee and hip osteoarthritis: interim analysis results of an observational study. Ann Rheum Dis. 2020;79:1747.

Лила АМ, Алексеева ЛИ, Бабаева АР и др. Возможности фармакологического лечения остеоартрита: фокус на симптоматические медленно действующие препараты (SYSADOA) и индивидуальные особенности пациента. Резолюция международного совещания экспертов. Современная ревматология. 2019;13(4):143-7.

Lila AM, Alekseeva LI, Babaeva AR, et al. Vozmozhnosti farmakologicheskogo lecheniya osteoartrita: fokus na simptomaticheskie medlenno deistvuyushchie preparaty (SYSADOA) i individual'nye osobennosti patsienta. Rezolyutsiya mezhdunarodnogo soveshchaniya ekspertov. Sovremennaya revmatologiya. 2019;13(4):143-7. (In Russ.).

Bell GA, Kantor ED, Lampe JW et al. Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol. 2012 Aug; 27(8):593-603. doi: 10.1007/s10654-012-9714-6. Epub 2012 Jul 25.

Ma H, Li X, Sun D, Zhou T, et al. Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. BMJ. 2019 May 14;365:l1628. doi: 10.1136/bmj.l1628.

King DE, Xiang J. Glucosamine/ Chondroitin and Mortality in a US NHANES Cohort. J Am Board Fam Med. Nov-Dec 2020;33(6):842-7. doi: 10.3122/jabfm.2020.06.200110.

The authors declare that there are no conflicts of interest present.